GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Price-to-Operating-Cash-Flow

TXMD (TherapeuticsMD) Price-to-Operating-Cash-Flow : 6.07 (As of Jun. 28, 2025)


View and export this data going back to 2002. Start your Free Trial

What is TherapeuticsMD Price-to-Operating-Cash-Flow?

As of today (2025-06-28), TherapeuticsMD's share price is $1.105. TherapeuticsMD's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.18. Hence, TherapeuticsMD's Price-to-Operating-Cash-Flow Ratio for today is 6.07.

The historical rank and industry rank for TherapeuticsMD's Price-to-Operating-Cash-Flow or its related term are showing as below:

TXMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.86   Med: 3.05   Max: 21.07
Current: 6.16

During the past 13 years, TherapeuticsMD's highest Price-to-Operating-Cash-Flow Ratio was 21.07. The lowest was 0.86. And the median was 3.05.

TXMD's Price-to-Operating-Cash-Flow is ranked better than
85.44% of 687 companies
in the Drug Manufacturers industry
Industry Median: 17.49 vs TXMD: 6.16

TherapeuticsMD's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $0.06. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.18.

During the past 13 years, TherapeuticsMD's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.50% per year. The lowest was -56.40% per year. And the median was -4.05% per year.


TherapeuticsMD Price-to-Operating-Cash-Flow Historical Data

The historical data trend for TherapeuticsMD's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Price-to-Operating-Cash-Flow Chart

TherapeuticsMD Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.60 - 8.51

TherapeuticsMD Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 8.51 5.08

Competitive Comparison of TherapeuticsMD's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Price-to-Operating-Cash-Flow falls into.


;
;

TherapeuticsMD Price-to-Operating-Cash-Flow Calculation

TherapeuticsMD's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=1.105/0.182
=6.07

TherapeuticsMD's Share Price of today is $1.105.
TherapeuticsMD's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

TherapeuticsMD Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Executives
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Paul Bisaro director
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017